SV2017005489A - Terapias de combinación para el tratamiento de cánceres - Google Patents

Terapias de combinación para el tratamiento de cánceres

Info

Publication number
SV2017005489A
SV2017005489A SV2017005489A SV2017005489A SV2017005489A SV 2017005489 A SV2017005489 A SV 2017005489A SV 2017005489 A SV2017005489 A SV 2017005489A SV 2017005489 A SV2017005489 A SV 2017005489A SV 2017005489 A SV2017005489 A SV 2017005489A
Authority
SV
El Salvador
Prior art keywords
cancer treatment
combination therapies
cancer
treatment
malignities
Prior art date
Application number
SV2017005489A
Other languages
English (en)
Inventor
Paolo Julie A Di
Randall Mark Jones
Daniel B Tumas
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2017005489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SV2017005489A publication Critical patent/SV2017005489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONAN EN EL PRESENTE DOCUMENTO MÉTODOS QUE SE RELACIONAN CON UNA ESTRATEGIA TERAPÉUTICA PARA EL TRATAMIENTO DEL CÁNCER, INCLUYENDO MALIGNIDADES HEMATOLÓGICAS. EN PARTICULAR, LOS MÉTODOS INCLUYEN LA ADMINISTRACIÓN DE ENTOSPLETINIB Y UN INHIBIDOR DE BCL-2, TAL COMO VENETOCLAX, NAVITOCLAX Y ABT-737
SV2017005489A 2015-02-03 2017-07-28 Terapias de combinación para el tratamiento de cánceres SV2017005489A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03

Publications (1)

Publication Number Publication Date
SV2017005489A true SV2017005489A (es) 2017-10-17

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005489A SV2017005489A (es) 2015-02-03 2017-07-28 Terapias de combinación para el tratamiento de cánceres

Country Status (25)

Country Link
US (2) US20180117052A1 (es)
EP (1) EP3253385A1 (es)
JP (1) JP2018503653A (es)
KR (1) KR20170104616A (es)
CN (1) CN107205992A (es)
AU (1) AU2016215643A1 (es)
BR (1) BR112017016019A2 (es)
CA (1) CA2974828A1 (es)
CL (1) CL2017001943A1 (es)
CO (1) CO2017007662A2 (es)
CR (1) CR20170352A (es)
CU (1) CU20170099A7 (es)
EA (1) EA201791516A1 (es)
EC (1) ECSP17048849A (es)
GT (1) GT201700167A (es)
IL (1) IL253573A0 (es)
MA (1) MA41449A (es)
MD (1) MD20170073A2 (es)
MX (1) MX2017009724A (es)
PE (1) PE20171241A1 (es)
PH (1) PH12017550063A1 (es)
SG (1) SG11201706107SA (es)
SV (1) SV2017005489A (es)
TW (1) TW201639573A (es)
WO (1) WO2016126552A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101743784B1 (ko) 2008-12-08 2017-06-05 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
MX350010B (es) 2010-03-11 2017-08-23 Gilead Connecticut Inc Inhibidores syk de imidazopiridinas.
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
WO2015084992A1 (en) 2013-12-04 2015-06-11 Gilead Sciences, Inc. Methods for treating cancers
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN108137578B (zh) * 2016-09-14 2021-02-05 杭州领业医药科技有限公司 Abt-199加成盐及其晶型、其制备方法和药物组合物
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
US11364235B2 (en) * 2017-04-28 2022-06-21 Actinium Pharmaceuticals, Inc. Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
CN111788203A (zh) 2018-01-10 2020-10-16 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
WO2020172431A1 (en) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Solid forms of condensed pyrazines as syk inhibitors
AU2020293230A1 (en) 2019-06-12 2022-01-27 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
US20220323465A1 (en) * 2019-12-04 2022-10-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CA3214527A1 (en) * 2021-04-05 2022-10-13 Doo-Young Jung Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
HUE030839T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
WO2010068257A1 (en) * 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Imidazopyrazine syk inhibitors
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
CA2771984A1 (en) 2009-09-20 2011-03-24 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
NZ701444A (en) 2010-08-27 2016-06-24 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
US20140235643A1 (en) 2011-10-04 2014-08-21 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
AU2013302617A1 (en) * 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
NZ630166A (en) * 2012-09-07 2017-01-27 Genentech Inc Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
UY35044A (es) 2012-09-24 2014-04-30 Gilead Sciences Inc ANTICUERPOS ANTI-dDr1
BR112015014592A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método para o tratamento de um humano
WO2014100765A1 (en) 2012-12-21 2014-06-26 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
AU2014277950B2 (en) 2013-06-14 2016-02-04 Gilead Calistoga Llc Phosphatidylinositol 3-kinase inhibitors
EA201690127A1 (ru) 2013-07-30 2016-07-29 Джилид Коннектикут, Инк. Состав на основе ингибиторов syk
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
EP2886146A1 (en) * 2013-12-20 2015-06-24 Sanofi-Aventis Deutschland GmbH Needle safety device and drug delivery device

Also Published As

Publication number Publication date
EA201791516A1 (ru) 2018-01-31
PH12017550063A1 (en) 2018-02-05
AU2016215643A1 (en) 2017-08-10
US20160220573A1 (en) 2016-08-04
MX2017009724A (es) 2017-11-17
CN107205992A (zh) 2017-09-26
KR20170104616A (ko) 2017-09-15
JP2018503653A (ja) 2018-02-08
CA2974828A1 (en) 2016-08-11
PE20171241A1 (es) 2017-08-24
ECSP17048849A (es) 2017-10-31
MA41449A (fr) 2017-12-12
CL2017001943A1 (es) 2018-03-02
IL253573A0 (en) 2017-09-28
EP3253385A1 (en) 2017-12-13
GT201700167A (es) 2017-11-02
CR20170352A (es) 2017-09-29
TW201639573A (zh) 2016-11-16
SG11201706107SA (en) 2017-08-30
CO2017007662A2 (es) 2017-10-20
BR112017016019A2 (pt) 2018-03-20
CU20170099A7 (es) 2018-03-13
WO2016126552A1 (en) 2016-08-11
MD20170073A2 (ro) 2018-02-28
US20180117052A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CR20150316A (es) Compuestos y sus métodos de empleo
NI201600071A (es) Compuestos de inhibidor de autotaxina
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
UY36075A (es) Derivados de tubulisina
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2017000391A1 (es) Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CL2017000050A1 (es) Terapia de combinación para el cáncer
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas